The Bill & Melinda Gates Foundation has highlighted critical challenges in Nigeria’s flagship REACH programme, aimed at reducing child mortality, citing drug clearance delays and concerns over antimicrobial resistance.
The Interim Director of the Foundation’s Nigeria Country Office, Uche Amaonwu, disclosed this on Tuesday at the 2024 REACH Network Annual Regional Meeting in Abuja, Nigeria’s Federal Capital Territory (FCT).
The REACH initiative — Resilience through Azithromycin in Children — is a major public health intervention across sub-Saharan Africa, leveraging biannual doses of azithromycin to reduce infant and under-five mortality in high-risk areas.
